501LBA LBA Orals: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)
Titel:
501LBA LBA Orals: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)
Auteur:
Herzberg, B. Johnson, M. Kim, C.G. Tolcher, A. Rodon, J. Mantia, C. Liu, J. Tripathi, A. Rodriguez, L. Paz-Ares De La Motte Rouge, T. Choi, C.M. Han, J.Y. Kwei, L. Liu, E. Sachdev, J. O’Quigley, M. White, M. Beaupre, D. Kim, H.R.